TY - JOUR
T1 - Immu-Mela
T2 - An open resource for exploring immunotherapy-related multidimensional genomic profiles in melanoma
AU - Yang, Jing
AU - Zhao, Shilin
AU - Wang, Jing
AU - Sheng, Quanhu
AU - Liu, Qi
AU - Shyr, Yu
N1 - Funding Information:
The authors would like to acknowledge funding from National Cancer Institute ( 5U01 CA163056--05 , U2C CA233291 and U54 CA217450 to Y.S.); Cancer Center Support Grant ( 2P30 CA068485-19 to Y.S.). Funding for open access charge: National Cancer Institute ( 5U01 CA163056-05 to Y.S.).
Publisher Copyright:
© 2021 The Authors
PY - 2021/5/20
Y1 - 2021/5/20
N2 - There are increasing studies aimed to reveal genomic hallmarks predictive of immune checkpoint blockade (ICB) treatment response, which generated a large number of data and provided an unprecedented opportunity to identify response-related features and evaluate their robustness across cohorts. However, those valuable data sets are not easily accessible to the research community. To take full advantage of existing large-scale immuno-genomic profiles, we developed Immu-Mela (http://bioinfo.vanderbilt.edu/database/Immu-Mela/), a multidimensional immuno-genomic portal that provides interactive exploration of associations between ICB responsiveness and multi-omics features in melanoma, including genetic, transcriptomics, immune cells, and single-cell populations. Immu-Mela also enables integrative analysis of any two genomic features. We demonstrated the value of Immu-Mela by identifying known and novel genomic features associated with ICB response. In addition, Immu-Mela allows users to upload their data sets (unrestricted to any cancer types) and co-analyze with existing data to identify and validate signatures of interest. Immu-Mela reduces barriers between researchers and complex genomic data, facilitating discoveries in cancer immunotherapy.
AB - There are increasing studies aimed to reveal genomic hallmarks predictive of immune checkpoint blockade (ICB) treatment response, which generated a large number of data and provided an unprecedented opportunity to identify response-related features and evaluate their robustness across cohorts. However, those valuable data sets are not easily accessible to the research community. To take full advantage of existing large-scale immuno-genomic profiles, we developed Immu-Mela (http://bioinfo.vanderbilt.edu/database/Immu-Mela/), a multidimensional immuno-genomic portal that provides interactive exploration of associations between ICB responsiveness and multi-omics features in melanoma, including genetic, transcriptomics, immune cells, and single-cell populations. Immu-Mela also enables integrative analysis of any two genomic features. We demonstrated the value of Immu-Mela by identifying known and novel genomic features associated with ICB response. In addition, Immu-Mela allows users to upload their data sets (unrestricted to any cancer types) and co-analyze with existing data to identify and validate signatures of interest. Immu-Mela reduces barriers between researchers and complex genomic data, facilitating discoveries in cancer immunotherapy.
UR - http://www.scopus.com/inward/record.url?scp=85107940911&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85107940911&partnerID=8YFLogxK
U2 - 10.1016/j.jgg.2021.03.016
DO - 10.1016/j.jgg.2021.03.016
M3 - Article
C2 - 34127402
AN - SCOPUS:85107940911
VL - 48
SP - 361
EP - 368
JO - Journal of Genetics and Genomics
JF - Journal of Genetics and Genomics
SN - 1673-8527
IS - 5
ER -